Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
OPTIMINE (azatadine maleate) is an oral first-generation antihistamine tablet approved in 1977 for allergic conditions. The drug works by blocking histamine receptors to reduce allergic symptoms such as urticaria, pruritus, and allergic rhinitis. It represents a legacy small-molecule therapeutic from the era before second-generation antihistamines became standard of care.
With lifecycle status approaching loss of exclusivity and minimal current market presence, commercial teams are likely focused on managed decline and cost optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job openings and approaching loss of exclusivity, OPTIMINE roles are limited and focused on managing a declining legacy asset rather than driving growth. Career opportunities center on operational efficiency, regulatory maintenance, and graceful product transition—suitable for professionals seeking portfolio management or turnaround experience rather than high-visibility commercial launches.
Worked on OPTIMINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.